Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 10, 2008
- GS1 Healthcare Tokyo Conference Calls For Use of GS1 Codes
November 10, 2008
- Lenalidomide Shows Teratogenicity: Celgene
November 10, 2008
- Daiichi Sankyo: Increases in Number of MRs in the US, Europe Impact on Profits
November 10, 2008
- R&D NEWS IN BRIEF
November 10, 2008
- Eisai: Aricept, MGI Pharma's Products Push Up Sales 9.9%
November 10, 2008
- JSMI Adds 20 APIs as Candidates for Switch OTC Drugs
November 10, 2008
- MTPC: Sales Down 0.7% Despite Strong Growth of Remicade, Mearubik
November 10, 2008
- Taisho: Strong Self-med. Business Makes Up for Slump of Ethical Drugs Business
November 10, 2008
- DSP: New Products Make Up for Decreases in Sales of Amlodin
November 10, 2008
- SSP: Sales Remain Soft but Profits Jump
November 10, 2008
- OPINION／Passion and Principles: Keys to Unlocking Talent
November 3, 2008
- ASKA Obtains Approval for Menoaid Combipatch
November 3, 2008
- Korosho to Review Opinions Received on Online Sale of OTC Drugs
November 3, 2008
- Daiichi Sankyo Responds to Speculation on Status of Prasugrel NDA
November 3, 2008
- Olympus Launches Endo Capsule
November 3, 2008
- PMDA to Increase Staff with Academic Background in Natural Sciences
November 3, 2008
- Korosho to Optimize Approved Doses for 4 Thiazide Diuretics
November 3, 2008
- NEW PRODUCTS
November 3, 2008
- Irribow Drug of Choice for Diarrhea-Predominant IBS
November 3, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…